<?xml version="1.0" encoding="UTF-8"?>
<ref id="B120">
 <label>120.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name name-style="western">
    <surname>Assoun</surname>
    <given-names>S</given-names>
   </name>
   <span xml:space="preserve" class="x" xmlns="http://www.w3.org/1999/xhtml">, </span>
   <name name-style="western">
    <surname>Brosseau</surname>
    <given-names>S</given-names>
   </name>
   <span xml:space="preserve" class="x" xmlns="http://www.w3.org/1999/xhtml">, </span>
   <name name-style="western">
    <surname>Steinmetz</surname>
    <given-names>C</given-names>
   </name>
   <span xml:space="preserve" class="x" xmlns="http://www.w3.org/1999/xhtml">, </span>
   <name name-style="western">
    <surname>Gounant</surname>
    <given-names>V</given-names>
   </name>
   <span xml:space="preserve" class="x" xmlns="http://www.w3.org/1999/xhtml">, </span>
   <name name-style="western">
    <surname>Zalcman</surname>
    <given-names>G</given-names>
   </name>
  </person-group>
  <article-title>Bevacizumab in advanced lung cancer: state of the art</article-title>. 
  <source>Future Oncol.</source>
  <volume>13</volume>(
  <issue>28</issue>), 
  <fpage>2515</fpage>â€“
  <lpage>2535</lpage> (
  <year>2017</year>).
  <pub-id pub-id-type="pmid">28812378</pub-id>
 </mixed-citation>
</ref>
